findmyKOL

Karina Serban, MD

Basic profile

University of Florida Health

ORCID↗NPI↗
✓ Full record
RegionGainesville, FL · SoutheastSpecialtyPulmonary DiseaseFocusRespiratory
Active KOLfindmyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2023–2026Why? →

Karina Serban is a Respiratory physician affiliated with University of Florida Health. OpenAlex indexes 105 publications with 899 citations (h-index 19); ClinicalTrials.gov lists 3 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
105publications

Distinct works indexed by OpenAlex, matched via ORCID.

899citations

Total citations across indexed works.

19h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials ↓
5companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2023–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1600 SW Archer Rd
Gainesville, FL 326103001

Telephone

352-273-8737

Provider last certified this registry record 3 Oct 2023.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    44.6%
    Human alpha-1 Proteinase Inhibitor44.6%
    Prolastin C65%Zemaira36%
    Part D<11 patients
  • Respiratory

    36.7%
    Corticosteroid14.4%
    Trelegy Ellipta100%
    Part D<11 patients
    beta2-Adrenergic Agonist12.2%
    Albuterol Sulfate Hfa100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    10.8%
    Corticosteroid10.8%
    Prednisone100%
    Part D<11 patients
Where care is delivered (Part B)70.6% facility · 29.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”